Martin Kunz serves as Senior Vice President - Operation of the Company. Previously, he served as President of Eurofins Genomics US from June 2010 to January 2019. Prior to serving as President, he served as Chief Technology Officer from September 2008 to June 2010 where his focus was building IT off-shore capacity and designing a new IT systems landscape for genomics services. Preceding his time at Eurofins, he served as Chief Information Officer of Operon Biotechnologies, Inc. from September 2005 to September 2008 where he built a global Previously, he served as President of Eurofins Genomics US from June 2010 to January 2019. Prior to serving as President, he served as Chief Technology Officer from September 2008 to June 2010 where his focus was building IT off-shore capacity and designing a new IT systems landscape for genomics services. Preceding his time at Eurofins, he served as Chief Information Officer of Operon Biotechnologies, Inc. from September 2005 to September 2008 where he built a global.
Martin Kunz is 49, he's been the Senior Vice President - Operation of Twist Bioscience Corp since 2019. There are 17 older and 4 younger executives at Twist Bioscience Corp. The oldest executive at Twist Bioscience Corp is Dr. William Charles Banyai Ph.D., 66, who is the Sr. VP of Advanced Devel., GM of Data Storage & Director.
Martin's mailing address filed with the SEC is C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158.
Over the last 6 years, insiders at Twist Bioscience Corp have traded over 141,837,821$ worth of Twist Bioscience Corp stock and bought 168,550 units worth 2,482,088$ . The most active insiders traders include Fred B Craves、Keith Crandell、Emily M. Leproust. On average, Twist Bioscience Corp executives and independent directors trade stock every 8 days with the average trade being worth of 465,824$. The most recent stock trade was executed by Dennis Cho on 6 September 2024, trading 275 units of TWST stock currently worth 10,769$.
at twist bioscience, our expertise is synthetic dna. we have developed a proprietary semiconductor-based synthetic dna manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. by synthesizing dna on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic dna production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. the twist bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. for more information, please visit www.twistbioscience.com .
Twist Bioscience Corp executives and other stock owners filed with the SEC include: